

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2

Jéromine Klingler^{1,2}, Svenja Weiss^{1,2}, Vincenza Itri¹, Xiaomei Liu^{1,2}, Kasopofoluwa Y. Oguntuyo³, Christian Stevens³, Satoshi Ikegame³, Chuan-Tien Hung³, Gospel Enyindah-Asonye¹, Fatima Amanat^{3,4}, Ian Baine⁵, Suzanne Arinsburg⁵, Juan C. Bandres², Erna Milunka Kojic⁶, Jonathan Stoeber⁷, Denise Jurczynszak^{3,4}, Maria Bermudez-Gonzalez³, Viviana Simon^{1,3,8}, Arthur Nádas⁹, Sean Liu^{1,3}, Benhur Lee³, Florian Krammer³, Susan Zolla-Pazner^{1,3*}, Catarina E. Hioe^{1,2,3*}

¹Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA.

²James J. Peters VA Medical Center, Bronx, NY, USA.

³Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

⁴Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

⁵Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

⁶Division of Infectious Diseases, Department of Medicine, Mount Sinai West and Morningside, NY, USA.

⁷Pulmonary and Critical Care Medicine, Mount Sinai West, NY, USA.

⁸Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA.

⁹Department of Environment Medicine, NYU School of Medicine, New York, NY, USA

24

25 *Co-corresponding author

26 Contact: catarina.hioe@mssm.edu, catarina.hioe@va.gov

27

28 **Abstract**

29 SARS-CoV-2 has infected millions of people globally. Virus infection requires the receptor-
30 binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and -
31 RBD antibodies to be protective in animal models and convalescent plasma as a promising
32 therapeutic option, little is known about immunoglobulin (Ig) isotypes capable of blocking
33 infection. Here, we studied spike- and RBD-specific Ig isotypes in convalescent and acute
34 plasma/sera. We also determined virus neutralization activities in plasma/sera, and purified Ig
35 fractions. Spike- and RBD-specific IgM, IgG1, and IgA1 were produced by all or nearly all
36 subjects at variable levels and detected early after infection. All samples also displayed
37 neutralizing activity. Regression analyses revealed that IgM and IgG1 contributed most to
38 neutralization, consistent with IgM and IgG fractions' neutralization potency. However, IgA also
39 exhibited neutralizing activity at a lower potency. Together, IgG, IgM and IgA are critical
40 components of convalescent plasma used for COVID-19 treatment.

41

42 **Keywords**

43 SARS-CoV-2, COVID-19, antibody isotypes, neutralization, convalescent plasma

44 **Background**

45 In December 2019, the first patients with coronavirus disease 2019 (COVID-19), caused
46 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were identified in Wuhan's
47 city of Hubei Province, China¹. Since then, the epidemic has rapidly spread to most regions of
48 the world, infecting millions of people². Effective therapeutics and vaccines against SARS-CoV-
49 2 are urgently needed. Convalescent plasma transfusion showed promising results in patients
50 with severe to life-threatening COVID-19³⁻⁷ and clinical trials to evaluate the efficacy of
51 convalescent plasma treatment for ambulatory and hospitalized COVID-19 patients are
52 underway⁸⁻¹¹. To this end, more information about the Ig isotypes present in the plasma of
53 COVID-19 convalescent individuals and their antiviral activities are needed. It is also unclear
54 which of the immunoglobulin (Ig) isotypes present in convalescent plasma are protective. The
55 data would likewise inform vaccine development, as more than 100 vaccine candidates are in
56 different stages of preclinical development, and many are now in phase 2 and 3 clinical trials¹².
57 Although using different strategies¹³, most vaccines are based on the SARS-CoV-2 spike
58 protein^{14,15}, which is a membrane-anchored protein present with two others (membrane and
59 envelope proteins) on the virus envelope surface and contains the receptor-binding domain
60 (RBD) required for binding to and entry into the cells¹⁶⁻²². These vaccines aim to protect by
61 inducing neutralizing antibodies (Abs) capable of blocking viral infection.

62 Monomeric IgG constitutes approximately 75% of the Abs found in serum and exists as
63 four subtypes: IgG1 (~66% of IgG), IgG2 (~23% of IgG), IgG3 (~7% of IgG) and IgG4 (~4% of
64 IgG)^{23,24}. IgM Abs represent 10% of total serum Abs and are the first to arise in response to new
65 antigens^{24,25}. Although IgM Abs do not undergo extensive somatic hypermutation to increase
66 their affinity as do IgG and IgA Abs, their higher valency due to oligomerization enhances their

67 avidity and potency against pathogens^{24,26,27}. IgA Abs exist as two subtypes: IgA1 and IgA2,
68 representing 15% of total serum Abs. IgA1 is the primary IgA subtype in serum while IgA2
69 predominates in mucosal secretions²⁴. These two IgA subtypes are dimeric in the mucosa, but in
70 the circulation, they are monomeric.

71 SARS-CoV-2 spike-, RBD- and nucleocapsid-specific serum/plasma Abs of IgM, IgG,
72 and IgA isotypes are found in most COVID-19 patients²⁸⁻³⁵, with Ab neutralizing activities
73 reported developing within the first two weeks of infection and decline over time^{31,33,36-38}.
74 However, the neutralizing titers appear to vary greatly^{31,33,36-38}, and they correlate with Ab
75 binding levels against RBD, spike, and/or nucleocapsid, and with age, duration of symptoms, and
76 symptom severity^{31,33,37}. Several RBD-specific monoclonal Abs of IgG isotype with potent
77 antiviral activities have been generated from individuals with high neutralization titers, and these
78 confer protection in animal models^{31,36,39,40}. Moreover, a monoclonal Ab of IgA isotype capable
79 of recognizing both the SARS-CoV-1 and SARS-CoV-2 spike proteins and blocking ACE2
80 receptor binding was recently described⁴¹. However, no direct evidence is available regarding the
81 neutralizing capacity of plasma IgM and IgA Abs from COVID-19 patients.

82 Studies on other respiratory viruses such as influenza show that, in addition to IgG, IgA
83 could also mediate virus neutralization, and their relative contribution depends on the
84 physiologic compartment in which they are found, with IgA contributing to the protection of
85 mostly the upper respiratory tract while IgG was protective of the lower respiratory tract⁴²⁻⁴⁵. Of
86 note, an anti-hemagglutinin monoclonal polymeric IgA has been demonstrated to mediate more
87 potent antiviral activities against influenza when compared to a monoclonal IgG against the same
88 epitope⁴⁶. Interestingly, an IgM Ab with potent antiviral activities targeting influenza B's
89 receptor binding site has also been described⁴⁷. In addition, respiratory syncytial virus (RSV)-

90 specific mucosal IgA neutralizing Abs are a better correlate of protection than RSV-specific
91 serum IgG neutralizing Abs⁴⁸. In the case of SARS-CoV-1, high titers of mucosal IgA in the
92 lungs correlated with reduced pathology upon viral challenge in animal models⁴⁹. Whether IgA
93 in the blood and in the respiratory tract's mucosa offers protection against SARS-CoV-2
94 infection or COVID-19 disease remains an open question. Moreover, few data are available
95 regarding the contribution of IgM to neutralization and protection against viruses, including
96 SARS-CoV-2. Of note, in terminally ill COVID-19 patients, systemic SARS-CoV-2 infection
97 affecting multiple organs including the heart, kidneys, and brain, is evident from autopsy
98 studies⁵⁰⁻⁵². Thus, the capacity of plasma Ig to suppress virus spread to these organs is critical for
99 effective convalescent plasma therapy against severe COVID-19 disease.

100 We recently described a multiplex bead Ab binding assay using the Luminex technology
101 to detect total Ig against spike and RBD⁵³. Based on this assay, we characterized the Ig isotype
102 profiles against spike and RBD in the plasma and serum from acutely infected or convalescent
103 individuals using this Luminex assay which detects antigen-specific IgM, IgG1-4, IgA1, and
104 IgA2. Using a pseudovirus assay⁵⁴, we also measured neutralizing activities in plasma, serum,
105 and Ig isotype plasma fractions to determine the neutralizing capacity of IgM, IgA, and IgG. The
106 data indicated a high prevalence of spike- and RBD-specific IgM and IgA Abs, similar to that of
107 IgG1, in plasma and serum from COVID-19 patients, and their contributions to virus neutralizing
108 activities. By testing purified IgG, IgM and IgA Abs from plasma of convalescent COVID-19
109 subjects, this study presents the first direct evidence that plasma IgG, IgM, and IgA all contribute
110 to SARS-CoV-2 neutralization.

111 **Results**

112 **Levels of Ig isotypes against the SARS-CoV-2 spike and RBD vary in convalescent**

113 **individuals.** A total of 29 serum (P#5-8) and plasma (TF#1-25) specimens from COVID-19-
114 convalescent individuals was tested. TF#1-25 were collected between March 26 and April 7,
115 2020, about 4-8 weeks after the initial outbreak in North American, and used for transfusion into
116 hospitalized COVID-19 patients³. Ten plasma from COVID-negative contemporaneous blood
117 bank donors (N#4-13) were included for comparison. Sera or plasma from 12 uninfected
118 individuals banked prior to the COVID-19 outbreak (N#1-3 and N#14-22) were used to establish
119 background values. The specimens were initially titrated for total Ig against spike and RBD (**Fig.**
120 **1**). All 29 COVID-19 positive specimens exhibited titration curves of total Ig Abs against spike,
121 while none of the negative controls did. Similar results were observed with RBD, except that one
122 contemporaneous COVID-19-negative sample had low levels of RBD-specific Ig (N#10).
123 Overall the background MFI values were higher for RBD than spike. To assess the
124 reproducibility of the assay, the samples were tested in at least two separate experiments run on
125 different days, and a strong correlation was observed between the MFI values from these
126 independent experiments (**Supplementary Fig. 1**). The areas under the curves (AUCs) highly
127 correlated with the MFI values from specimens diluted 1:200 ($p < 0.0001$; **Supplementary Fig.**
128 **2**); consequently, all samples were tested for isotyping at this dilution. At the 1:200 dilution we
129 were able to discern a diverse range of Ig isotype levels among individual samples (**Fig. 2**). To
130 evaluate for the presence of spike-specific and RBD-specific total Ig, IgM, IgG1, IgG2, IgG3,
131 IgG4, IgA1 and IgA2, the specificity and strength of the secondary Abs used to detect the
132 different isotypes were first validated with Luminex beads coated with myeloma proteins of
133 known Ig isotypes (IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and IgM). All eight secondary Abs
134 were able to detect their specific Ig isotypes with MFI values reaching $> 60,000$
135 (**Supplementary Fig. 3**).

136 All 29 convalescent individuals had anti-spike and anti-RBD total Ig (**Fig. 2**), but the Ig
137 levels were highly variable, with MFI values ranging from 36,083 to 190,150. In addition, all 29
138 convalescent individuals also displayed IgM Abs against spike at varying levels, and 93% were
139 positive for anti-RBD IgM when evaluated using cut-off values calculated as mean + 3 standard
140 deviation (SD) of the 12 pre-pandemic samples (**Fig 2b, c**). An IgG1 response was detected
141 against both spike and RBD in 97% of the convalescent subjects, with MFI values that ranged
142 from 1,013 to 59,880. In contrast, IgG2, IgG3, and IgG4 Abs against spike and RBD were
143 detected in only a small fraction of the subjects, and the levels were very low (MFI values <
144 1,300) (**Fig. 2**). Surprisingly, almost all individuals produced IgA1 Abs against spike (97%) and
145 RBD (93%), while 17% exhibited IgA2 against spike, and 48% exhibited IgA2 against RBD
146 (**Fig. 2**). Low levels, slightly above cut-off, of spike- and RBD-binding total Ig, IgM, and IgG1,
147 and IgA1 were also detected sporadically in contemporaneous COVID-19 samples, such as N#8,
148 N#10, and N#11. The responses against spike and RBD were highly correlated for every isotype
149 (**Supplementary Fig. 4**). Overall, these data demonstrate that IgM, IgG1, and IgA1 Abs were
150 induced against spike and RBD in all or almost all COVID-19 convalescent individuals (**Fig. 2**).
151 The levels, however, were highly variable among individuals. No statistical significance in the
152 levels of total Ig, IgM, IgG1, and IgA1 was observed between female and male individuals
153 (**Supplementary Fig. 5**).

154 In **Fig. 3**, regression analyses to assess the impact of individual isotypes on the total Ig
155 binding showed that IgG1 had the highest r^2 values (0.83 and 0.70 for spike- and RBD-binding
156 IgG1, respectively) with $p < 0.0001$, indicating that IgG1 is the major isotype induced by SARS-
157 CoV-2 infection against spike and RBD (**Fig. 3a,b**). IgG2 Abs against RBD had an r^2 value of
158 0.55 with $p < 0.0001$, but IgG2 levels were very low. For all other isotypes, including IgM, the r^2

159 values were less than 0.40 (**Fig. 3c**). Thus, despite the presence of many isotypes in sera and
160 plasma, as expected, the major isotype is IgG1.

161 Specimens from two patients (P#1 and P#2) were drawn during the acute phase of the
162 infection. Serial specimens from these patients were tested to determine the isotypes of Abs
163 present early in infection. The earliest samples from both patients, drawn at 7 or 8 days after
164 symptom onset were already positive for total Ig, IgG1, IgA1 and IgM Abs against spike
165 (**Supplementary Fig. 6a**) and RBD (**Supplementary Fig. 6b**), and these levels increased over
166 the following three to seven days. On the contrary, IgA2 Ab levels were near or below
167 background on days 7-8 and remained unchanged over two weeks post-onset. IgG4 Abs also
168 remained low or near background, whereas IgG2 and IgG3 Abs increased slightly to above
169 background after 10-15 days.

170 **Neutralizing activities are detected in all convalescent COVID-19 individuals.** We
171 subsequently tested the ability of samples from convalescent subjects to neutralize a VSVΔG
172 pseudovirus bearing the SARS-CoV-2 spike protein (COV2pp). This pseudovirus assay
173 demonstrated a strong positive correlation with neutralization of the authentic SARS-CoV-2
174 virus ($p = 0.82$ and $p < 0.0001$ for IC_{50} correlation)⁵⁴. The results, shown in **Fig. 4**, demonstrate
175 the percentages of COV2pp neutralizing activity in serum or plasma specimens from 28 COVID-
176 19-convalescent individuals and 11 COVID-19-negative individuals over a range of seven serial
177 four-fold dilutions. A soluble recombinant RBD (sRBD) protein capable of blocking virus
178 infection was tested in parallel as a positive control.

179 All specimens from COVID-19-convalescent individuals were able to neutralize the virus
180 at levels above 50% (**Fig. 4a**). For 26 of 28 specimens, neutralization reached more than 90%
181 (**Fig. 4a**). The sample with the lowest titer (reciprocal IC_{50} titer = 37) reached a neutralization

182 plateau of only ~60%. Of note, one sample (TF#11) demonstrated highly potent neutralization
183 with a reciprocal IC₅₀ titer > 40,960, and neutralization was still 75% at the highest dilution
184 tested. None of the samples from COVID-19-negative individuals reached 50% neutralization
185 (**Fig. 4b**), while the sRBD positive control demonstrated potent neutralization with an IC₅₀ of
186 0.06 µg/mL (**Fig. 4c**), similar to that recently reported⁵⁴.

187 The samples were also tested for neutralization against a COV2pp bearing spike with a
188 D614 mutation (D614G mutant), as the D614G variant has become the most prevalent
189 circulating strain in the global pandemic⁵⁵. Similar to the WT COV2pp, all COVID-19-
190 convalescent samples had neutralizing activity reaching >50% (**Fig. 4d**), while none of the
191 negative samples did (**Fig. 4e**). The IC₉₀ titers against WT and D614 mutant differed on average
192 by only 1.7-fold and correlated strongly with each other (**Fig. 4f**).

193 **IgM and IgG1 contribute most to SARS-CoV-2 neutralization.** Given our observation
194 that Ab isotype levels and neutralization titers varied tremendously among convalescent COVID-
195 19 individuals (**Figs. 2 and 5**), we investigated the relative contribution of each Ab isotype to the
196 neutralizing activities. Regression analyses were performed on 27 COVID-19-convalescent
197 samples (TF#11 was excluded due to its outlier neutralization titer). As expected, relatively high
198 r² values (0.32 – 0.62) and significant p values were observed with total Ig, IgM and IgG1; in
199 each case, r² values were higher for spike than for RBD (**Fig. 6a**). For other isotypes, significant
200 p values were sporadically achieved, but r² values were weak (**Fig. 6a,b**).

201 **Neutralizing activities are mediated by IgM, IgG, and IgA fractions.** To assess
202 directly the capacity of different isotypes to mediate neutralization, we evaluated the
203 neutralization activities of IgM, IgG, and IgA fractions purified from the plasma of five COVID-
204 19-convalescent individuals (RP#1-5). The enrichment of IgM, IgG1, and IgA1 Abs reactive

205 with spike and RBD was validated using the isotyping method used above (**Supplementary Fig.**
206 **7** and not shown). These IgM, IgG, and IgA fractions were then evaluated for neutralizing
207 activity along with the original plasma (**Fig. 7**). The RP#1-5 plasma neutralizing reciprocal IC₅₀
208 titers ranged from 35 to 690 (**Fig. 7a,b**). Purified IgM and IgG fractions from RP#1-5 all
209 mediated neutralization reaching more than 50%. Unexpectedly, plasma IgA fractions also
210 displayed neutralizing activity, although not to the same potency as IgM and IgG (**Fig 7c,d**). In
211 contrast, IgM, IgG, and IgA fractions from the negative control (RN#1) showed no neutralization
212 (**Fig. 7c,d**).

213 **Discussion**

214 Our study demonstrated that IgG1, IgA1 and IgM Abs against spike and RBD were
215 highly prevalent in the plasma samples of convalescent COVID-19 patients approximately one to
216 two months after infection. The presence of these isotypes was detected within 7-8 days after the
217 onset of symptoms. Importantly, all three isotypes show the capacity to mediate virus
218 neutralization. While regression analyses indicate the strongest contribution of IgM and IgG1
219 Abs to neutralizing activity, direct testing of purified isotype fractions showed that IgA also
220 contributed to neutralizing activity, indicating the protective potential of all three major Ig
221 isotypes. These data carry important implications for the use of convalescent plasma and
222 hyperimmunoglobulin as COVID-19 therapeutic modalities, suggesting that the selection be
223 based on the measurement of all of these Ig isotypes.

224 While all COVID-19 convalescent individuals exhibited plasma/serum neutralization
225 activities reaching 50% neutralization, and 26 of 28 specimens attained 90% neutralization,
226 neutralization levels were highly variable with reciprocal IC₅₀ and IC₉₀ titers ranging over three
227 orders of magnitude. The titers were comparable against the initial Wuhan strain and the

228 currently prevalent D614G strain. Similarly, the levels of spike- and RBD-binding total Ig and Ig
229 isotypes varied greatly.

230 A trend toward higher levels of total Ig and each Ig isotype was seen in female compared
231 to male subjects, as reported in another study⁵⁶. Moreover, except for TF#11 (a male elite
232 neutralizer), the median neutralizing reciprocal IC₉₀ titer was higher in females than males,
233 although the difference did not reach significance (data not shown). Sex differences in Ab
234 induction have been observed following vaccination against influenza in humans and mice and
235 were shown to result from the impact of sex steroids^{57,58}. Whether and to what extent this
236 contributes to sex differences seen in clinical outcomes of COVID-19⁵⁹ remains to be
237 investigated. Other studies have shown that the Ab levels were associated with multiple factors,
238 including time from disease onset⁶⁰ and disease severity³⁰. However, other than sex, clinical data
239 are not available for the subjects studied here, limiting our analysis only to neutralization and Ig
240 isotypes.

241 One remarkable finding from our study is that although neutralization titers correlated
242 with binding levels of IgM and IgG1 and not with those of IgA1 or IgA2, purified IgA fractions
243 from convalescent COVID-19 patients exhibited significant neutralizing activities. The
244 importance of this finding is underscored by the data showing that IgA1 was the prominent
245 isotype in some plasma samples such as TF#7 and TF#24 and that IgA1 could be detected early,
246 within a week after symptom onset. Data from other studies also supported IgA's significance in
247 that purified IgA fractions exhibited more or as potent neutralizing activities compared to
248 purified IgG and that RBD-binding IgA correlated as strongly as the IgG equivalent with micro-
249 neutralization titers^{61,62}. The presence of IgA was also detected in the saliva and bronchoalveolar
250 lavage samples from COVID-19 patients^{62,63}. Nonetheless, Wang *et al.* reported that plasma IgA

251 monomers were less potent than the plasma IgG and secretory IgA counterparts⁶⁴. In our study,
252 neutralization activities detected in the IgA fractions were mediated mainly by IgA1, the
253 predominant IgA isotype in the plasma, and the IC₅₀ potency of the IgA fraction was ~4-fold
254 lower than those of IgM and IgG1 fractions. This difference cannot be explained entirely by
255 lower amounts of spike-specific IgA1 in the tested fractions, as estimations using spike-specific
256 monoclonal antibodies of the respective isotypes yielded similar concentrations in IgA1 and IgM
257 fractions (median of 2 and 2.5 µg/mL respectively). Fine epitope specificity and affinity may
258 differ for IgA, IgM, and IgG to impact neutralization potency, but are yet to be evaluated.

259 In addition to neutralization, non-neutralizing Ab activities have been implicated in
260 protection from virus infection through potent Fc-mediated functions such as antibody-dependent
261 cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and
262 complement-mediated lysis; this is reported for HIV, influenza, Marburg, and Ebola viruses^{44,65–}
263 ⁶⁸. The Fc activities were not evaluated in our study, and their contribution to protection against
264 infection and disease progression in humans is yet unclear^{15,69–71}. Interestingly, a recent study
265 demonstrated enrichment of spike-specific IgM and IgA1 Abs and spike-specific phagocytic and
266 antibody-dependent complement deposition (ADCD) activity in plasma of individuals who
267 recovered from a SARS-CoV-2 infection, while nucleocapsid-specific IgM and IgA2 responses
268 and nucleocapsid-specific ADCD activity were features enriched in deceased patients⁷². DNA
269 vaccines expressing full-length and truncated spike proteins could curtail SARS-CoV-2 infection
270 in the respiratory tract by varying degrees in rhesus macaques. Virus reduction correlated with
271 levels of neutralization and also Fc-mediated effector functions such as ADCD¹⁵. Interestingly,
272 these DNA vaccines elicited spike- and RBD-specific IgG1, IgG2, IgG3, IgA, and IgM Abs, and
273 similar to our findings, neutralization correlated most strongly with IgM. Adenovirus serotype 26

274 vaccine vectors encoding seven different SARS-CoV-2 spike variants showed varying protection
275 levels, and virus reduction correlated best with neutralizing Ab titers together with IgM binding
276 levels, FcγRII-binding, and ADCD responses⁷³. Defining the full potential of Abs against SARS-
277 CoV-2 that includes neutralizing, non-neutralizing and enhancing activities are vital for
278 determining the optimal convalescent Ab treatment against COVID-19 and assessing the
279 potential efficacy of COVID-19 vaccine candidates.

280 When we examined plasma specimens collected within 7-8 days after COVID-19
281 symptom onset, we detected IgG and IgA against spike and RBD, as well as IgM. This is
282 consistent with published reports showing that 100% of COVID-19-infected individuals
283 developed IgG within 19 days after symptom onset and that seroconversion for IgG and IgM
284 occurred simultaneously or sequentially³⁰. IgA was also found early after infection (4-6 days
285 after symptom onset) and increased over time in several other studies^{28,35,63,74}. These studies
286 suggest that measuring total Ig, rather than IgG, would provide a better outcome for early disease
287 diagnosis. Indeed, we found no correlation between the levels of different isotypes examined in
288 our study (data not shown). This lack of correlation may result from their asynchronous,
289 sequential induction (IgM first, then IgG, and finally IgA). Still, IgA's presence early during
290 acute infection also suggests the potential contribution of natural IgA, which, similar to natural
291 IgM, arises spontaneously from innate B1 cells to provide the initial humoral responses before
292 the induction, maturation, and class-switching of adaptive classical B cells^{75,76}.

293 In summary, this study demonstrates that spike- and RBD-specific IgM, IgG1, and IgA1
294 Abs were present in serum and plasma of all or almost all analyzed COVID-19 convalescent
295 subjects and were detected at very early stages of infection. The plasma of convalescent
296 individuals also displayed neutralization activities mediated by IgM, IgG, and IgA1, although

297 neutralization titers correlated more strongly with IgM and IgG levels. The contribution of IgM,
298 IgG, and IgA Abs to the neutralizing activities against SARS-CoV-2 demonstrates their
299 importance in the efficacy of convalescent plasma used for COVID-19 treatment.

300 **Methods**

301 **Recombinant proteins.** The recombinant spike and RBD proteins were produced as
302 previously described⁷⁷ in Expi293F cells (ThermoFisher) by transfections of purified DNA using
303 an ExpiFectamine Transfection Kit (ThermoFisher). The soluble version of the spike protein
304 included the protein ectodomain (amino acids 1-1213), a C-terminal thrombin cleavage site, a T4
305 foldon trimerization domain, and a hexahistidine tag. The protein sequence was also modified to
306 remove the polybasic cleavage site (RRAR to A) and two stabilizing mutations (K986P and
307 V987P, wild type numbering). The RBD (amino acids 319-541) included the signal peptide
308 (amino acids 1–14) and a hexahistidine tag. Supernatants from transfected cells were harvested
309 three days after the transfection by centrifugation of the culture at 4000 g for 20 minutes. The
310 supernatant was then incubated with 6 mL Ni-NTA agarose (Qiagen) for one to two hours at
311 room temperature. Next, gravity-flow columns were used to collect the Ni-NTA agarose, and the
312 protein was eluted. Each protein was concentrated in Amicon centrifugal units (EMD Millipore)
313 and resuspended in phosphate buffered saline (PBS).

314 **Human samples.** Twenty-five citrated plasma of convalescent COVID-19 individuals
315 destined for transfusion to SARS-CoV-2-infected individuals (TF#1-25, collected between
316 March 26th and April 7th 2020) and ten specimens derived from the blood bank (N#4-13),
317 representing contemporary COVID-19-negative blood bank donors, were obtained from the
318 Division of Transfusion Medicine of the Department of Pathology, Molecular and Cell-Based
319 Medicine (Mount Sinai Hospital System, IRB #20-03574). Four additional de-identified serum

320 specimens from individuals with COVID-19 (P#5-8) were provided by the Clinical Pathology
321 Division of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn
322 School of Medicine at Mount Sinai. Serum and plasma samples were also obtained from study
323 participants enrolled in IRB-approved protocols at the Icahn School of Medicine at Mount Sinai
324 (Icahn School of Medicine at Mount Sinai IRB #16-00772, #16-00791, #17-01243) and the
325 James J. Peter VA Medical Center (IRB #BAN-1604). Samples from these protocols included
326 sera from seven participants with documented SARS-CoV-2 infection (P#1 d8, d11, and d15
327 after symptom onset, P#2 d7 and d10 after symptom onset, and RP#1-5 after convalescence), and
328 sera from twelve healthy donors (N#1-3, N#14-22) collected prior to the spread of SARS-CoV-2
329 in the USA. All study participants provided written consent at enrollment and agreed to sample
330 banking and future research use of their banked biospecimens. All samples were heat-inactivated
331 and/or treated with 0.05% Triton X-100 prior to use.

332 **Ig fractionation.** IgA was first isolated from plasma by mixing 1:2 diluted plasma with
333 peptide M agarose beads (600 μ L/28 mL plasma, InvivoGen #GEL-PDM) for 1.5 hours at room
334 temperature. Beads were then collected on a column and washed with PBS until protein reading
335 (280 nm) by Nanodrop reached background. IgA was eluted from beads with a pH 2.8 elution
336 buffer (Thermo Scientific #21004) and neutralized with pH 9 Tris buffer. The pass-through
337 plasma sample was collected for IgG enrichment using protein G agarose beads (InvivoGen
338 #GEL-AGG) using the same protocol as above and subsequently for IgM isolation using a
339 HiTrap IgM column (G.E. Healthcare #17-5110-01) according to the manufacturer's instruction.
340 An additional purification step was performed using Protein A Plus mini-spin columns to
341 separate IgG from IgM. Protein concentrations were determined with Nanodrop prior to use in
342 Luminex and neutralization experiments.

343 **Multiplex bead Ab binding assay.** The SARS-CoV-2 antigens used in this assay
344 consisted of a soluble recombinant trimerized form of the spike protein and a recombinant RBD
345 protein⁷⁸. Antigens were coupled to beads as previously described, with minor changes⁵³. Each
346 antigen was covalently coupled individually to a uniquely labeled fluorochrome carboxylated
347 xMAP bead set at 2.0 µg protein/million beads using a two-step carbodiimide reaction with the
348 xMAP Ab Coupling (AbC) Kit following to the manufacturers' instructions (Luminex, Austin,
349 TX). The coupled beads were pelleted, resuspended at 5x10⁶ beads/mL in storage buffer (PBS,
350 0.1% bovine serum albumin (BSA), 0.02% Tween-20, and 0.05% sodium azide, pH 7.4), and
351 stored at -80°C. Three to five million beads per batch were prepared in a 1.5 mL conical tube.

352 Before each experiment, the beads needed for a single run (2,500 beads/well x number of
353 wells) were pelleted and resuspended in assay buffer (PBS, 0.1% B.S.A., 0.02% Tween-20) to
354 deliver 2,500 beads in a volume of 50 µL/well in a 96-well plate. Sera/plasma samples were
355 serially titrated (1:50 to 1:6400 final dilution) or diluted in assay buffer to 1:100 (for a final
356 dilution of 1:200). The samples were then added as 50 µL/well to the wells containing the beads
357 and incubated at room temperature for 1 hour at 600 rpm. After two washes in assay buffer, 100
358 µL/well of biotinylated antibodies specific for total Ig, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or
359 IgM was added and incubated for 30 minutes at room temperature on a plate shaker; these
360 antibodies were rabbit biotinylated-anti-human total Ig (Abcam, catalog #ab97158) at 2 µg/mL,
361 mouse biotinylated-anti-human IgG1 Fc (Invitrogen #MH1515) at 4 µg/mL, mouse biotinylated-
362 anti-human IgG2 Fc (Southern Biotech #9060-08) at 1 µg/mL, mouse biotinylated-anti-human
363 IgG3 Hinge (Southern Biotech #9210-08) at 3 µg/mL, mouse biotinylated-anti-human IgG4 Fc
364 (Southern Biotech #9200-08) at 4 µg/mL, mouse biotinylated-anti-human IgA1 Fc (Southern
365 Biotech #9130-08) at 4 µg/mL, mouse biotinylated-anti-human IgA2 Fc (Southern Biotech

366 #9140-08) at 4 µg/mL or goat biotinylated-anti-human IgM (Southern Biotech #2020-08) at 3
367 µg/mL. After two washes, 100 µL/well of Streptavidin-Phycoerythrin (P.E.) at 1 µg/mL was
368 added (BioLegend #405204) followed by a 30 minutes incubation at room temperature on a plate
369 shaker. After two additional washes, 100 µL of assay buffer/well was added and put on a shaker
370 to resuspend the beads. Each plate was read with a Luminex Flexmap 3D instrument. Specimens
371 were tested in duplicate, and the results were recorded as mean fluorescent intensity (MFI).

372 **COV2pp production and titration.** The SARS-CoV-2 pseudoviruses (COV2pp) with
373 wild-type (WT) or D614G mutated spike proteins were produced as previously described⁵⁴.
374 Briefly, 293T cells were transfected to overexpress SARS-CoV-2 glycoproteins. For background
375 entry with particles lacking a viral surface glycoprotein, pCAGG empty vector was transfected
376 into 293T cells. Around 8 hours post-transfection, cells were infected with the VSVΔG-rLuc
377 reporter virus for 2 hours and then washed with PBS. Two days post-infection, supernatants were
378 collected and clarified by centrifugation at 1250 rpm for 5 minutes. At the time of collection, a
379 small batch of VSVΔG-rLuc particles bearing the CoV2pp was treated with TPCK-treated
380 trypsin (Sigma-Aldrich #T1426-1G) at room temperature for 15 minutes prior to inhibition with
381 soybean trypsin inhibitor (Fisher Scientific #1707502). Finally, particles were aliquoted prior to
382 storage in -80°C.

383 The pseudoviruses were titrated on 20,000 Vero-CCL81 cells seeded in a 96-well black
384 plate with clear bottom 24 hours before infection. At 18 to 22 hours post-infection, the infected
385 cells were washed with PBS and processed for detection of Renilla luciferase activity with
386 Renilla-Glo™ Luciferase Assay System (Promega #E2720). A Cytation3 (BioTek) instrument
387 was used to read luminescence.

388 **COV2pp neutralization.** The day before infection, 20,000 Vero-CCL81 cells per well

389 were seeded in a 96-well black plate with clear bottom. On the assay day, the COV2pp WT or
390 D614G virus was diluted based on the titration results, and 82.5 μ L added to all wells, except six
391 for cell control, of a 96-well V-bottom plate. The seven serial dilutions of the samples were then
392 prepared in another 96-well V-bottom plate. Samples of the COVID-19-infected individuals and
393 COVID-19-negative individuals were tested at 4-fold dilutions from 1:10 to 1:40,960. Purified
394 IgM, IgG, and IgA fractions and negative control fractions were tested at 4-fold dilutions from
395 500 to 0.02 μ g/mL. 27.5 μ L per well of the diluted sample was then added to the plate with the
396 pseudovirus. For each plate, six wells were kept with the virus only, as virus control, and six
397 wells with media only, as cell control. The plates were then incubated for 30 minutes at room
398 temperature. 100 μ L of the virus/sample mix or virus or medium alone was then added to the
399 cells and spinoculated by centrifugation at 1250 rpm for 1 hour at room temperature. After
400 incubation for 18 to 22 hours at 37°C, the measurement of infection/neutralization was performed
401 as described for the COV2pp titration.

402 The percentage of neutralization was calculated with the formula: $100 - ((\text{sample's R.L.U.} - \text{cell control R.L.U.}) / \text{virus control R.L.U.}) * 100$. The inhibitory concentration 50% (IC₅₀) and
403 90% (IC₉₀) were respectively defined as the reciprocal sample dilution or purified Ig fraction
404 concentration achieving 50% and 90% neutralization.

406 **Statistical analysis.** Statistical tests that included two-tailed Mann-Whitney test,
407 Spearman rank-order correlation test, and simple linear regressions were performed as
408 designated in the figure legends. All statistical tests were performed using GraphPad Prism 8.

409

410 **Data availability.**

411 The raw data that support the findings of this study are available from the corresponding
412 author upon request.

413

414

415 **References.**

416 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
417 Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020 20;382(8):727–33.

418 2. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Jun 29].
419 Available from: <https://covid19.who.int>

420 3. Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent
421 plasma treatment of severe COVID-19: a propensity score-matched control study. *Nat Med.*
422 2020 Sep 15;

423 4. Martinez-Resendez MF, Castilleja-Leal F, Torres-Quintanilla A, Rojas-Martinez A,
424 Garcia-Rivas G, Ortiz-Lopez R, et al. Initial experience in Mexico with convalescent plasma in
425 COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv.* 2020
426 Jul 20;2020.07.14.20144469.

427 5. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent
428 plasma therapy in patients with COVID-19. *Transfus Apher Sci Off J World Apher Assoc Off J*
429 *Eur Soc Haemapheresis.* 2020 Sep 19;102955.

430 6. Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The efficacy assessment of
431 convalescent plasma therapy for COVID-19 patients: a multi-center case series. *Signal Transduct*
432 *Target Ther.* 2020 Oct 6;5(1):1–12.

433 7. Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors

- 434 Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A
435 Prospective Phase II Clinical Trial. *Infect Dis Ther.* 2020 Sep 20;1–14.
- 436 8. Janssen M, Schäkel U, Fokou CD, Krisam J, Stermann J, Kriegsmann K, et al. A
437 Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects
438 after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe
439 SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised
440 controlled trial. *Trials.* 2020 Dec;21(1):1–4.
- 441 9. NIH expands clinical trials to test convalescent plasma against COVID-19 [Internet].
442 National Institutes of Health (NIH). 2020 [cited 2020 Oct 7]. Available from:
443 [https://www.nih.gov/news-events/news-releases/nih-expands-clinical-trials-test-convalescent-](https://www.nih.gov/news-events/news-releases/nih-expands-clinical-trials-test-convalescent-plasma-against-covid-19)
444 [plasma-against-covid-19](https://www.nih.gov/news-events/news-releases/nih-expands-clinical-trials-test-convalescent-plasma-against-covid-19)
- 445 10. Convalescent Plasma to Limit SARS-CoV-2 Associated Complications - Full Text View
446 - ClinicalTrials.gov [Internet]. [cited 2020 Nov 2]. Available from:
447 <https://clinicaltrials.gov/ct2/show/NCT04373460>
- 448 11. Convalescent Plasma in Outpatients With COVID-19 - Full Text View -
449 ClinicalTrials.gov [Internet]. [cited 2020 Nov 2]. Available from:
450 <https://clinicaltrials.gov/ct2/show/NCT04355767>
- 451 12. Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saviile M, et al. The COVID-
452 19 vaccine development landscape. *Nat Rev Drug Discov.* 2020 Apr 9;19(5):305–6.
- 453 13. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. *Immunity.* 2020 Apr 3;
- 454 14. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart SP, et al. Phase 1/2
455 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate
456 (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. *medRxiv.* 2020 Jul

457 1;2020.06.30.20142570.

458 15. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA
459 vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*. 2020 May 20;

460 16. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of
461 SARS-CoV-2 by full-length human ACE2. *Science*. 2020 27;367(6485):1444–8.

462 17. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel
463 coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular
464 protease TMPRSS2 for entry into target cells. *bioRxiv*. 2020 Jan 31;2020.01.31.929042.

465 18. Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host
466 cells via a novel route: CD147-spike protein. *bioRxiv*. 2020 Mar 14;2020.03.14.988345.

467 19. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
468 associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270–3.

469 20. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
470 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
471 *Lancet Lond Engl*. 2020 22;395(10224):565–74.

472 21. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.
473 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
474 Proven Protease Inhibitor. *Cell*. 2020 16;181(2):271-280.e8.

475 22. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure,
476 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020 16;181(2):281-
477 292.e6.

478 23. Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: From Structure to
479 Effector Functions. *Front Immunol [Internet]*. 2014 Oct 20 [cited 2018 Jun 12];5. Available

- 480 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202688/>
- 481 24. Schroeder HW, Cavacini L. Structure and function of immunoglobulins. *J Allergy Clin*
482 *Immunol.* 2010 Feb;125(2 Suppl 2):S41-52.
- 483 25. Boes M. Role of natural and immune IgM antibodies in immune responses. *Mol*
484 *Immunol.* 2000 Dec;37(18):1141–9.
- 485 26. Müller R, Gräwert MA, Kern T, Madl T, Peschek J, Sattler M, et al. High-resolution
486 structures of the IgM Fc domains reveal principles of its hexamer formation. *Proc Natl Acad Sci.*
487 2013 Jun 18;110(25):10183–8.
- 488 27. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the
489 twenty-first century. *Nat Rev Drug Discov.* 2003 Jan;2(1):52–62.
- 490 28. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG
491 responses in COVID-19. *Cell Mol Immunol.* 2020 Jul;17(7):773–5.
- 492 29. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets
493 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
494 Unexposed Individuals. *Cell.* 2020 Jun 25;181(7):1489-1501.e15.
- 495 30. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses
496 to SARS-CoV-2 in patients with COVID-19. *Nat Med.* 2020 Jun;26(6):845–8.
- 497 31. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent
498 antibody responses to SARS-CoV-2 in convalescent individuals. *Nature.* 2020 Jun 18;
- 499 32. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-
500 CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis Off Publ Infect Dis Soc*
501 *Am.* 2020 Mar 28;
- 502 33. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.

- 503 Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus
504 Disease Patients. *Emerg Infect Dis.* 2020 Jul;26(7):1478–88.
- 505 34. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral
506 Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis Off Publ Infect*
507 *Dis Soc Am.* 2020 Mar 21;
- 508 35. Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, et al. IgA-Ab response
509 to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. *Clin*
510 *Chim Acta.* 2020 Aug 1;507:164–6.
- 511 36. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited
512 by SARS-CoV-2 infection. *Nature.* 2020 May 26;
- 513 37. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to
514 SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv.* 2020
515 Apr 20;2020.03.30.20047365.
- 516 38. Prévost J, Gasser R, Beaudoin-Bussièrès G, Richard J, Duerr R, Laumaea A, et al. Cross-
517 Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell Rep Med.* 2020
518 Oct 20;1(7):100126.
- 519 39. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W, et al. Isolation of potent SARS-
520 CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*
521 [Internet]. 2020 Jun 15 [cited 2020 Jul 16]; Available from:
522 <https://science.sciencemag.org/content/early/2020/06/15/science.abc7520>
- 523 40. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently
524 neutralizing and protective human antibodies against SARS-CoV-2. *Nature.* 2020 Jul 15;1–10.
- 525 41. Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, et al. IgA MAb

- 526 blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. *BioRxiv Prepr Serv*
527 *Biol.* 2020 May 15;
- 528 42. Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of
529 influenza viral infection in the murine respiratory tract. *J Immunol Baltim Md* 1950. 2004 Aug
530 1;173(3):1978–86.
- 531 43. Suzuki T, Kawaguchi A, Aina A, Tamura S, Ito R, Multihartina P, et al. Relationship of
532 the quaternary structure of human secretory IgA to neutralization of influenza virus. *Proc Natl*
533 *Acad Sci U S A.* 2015 Jun 23;112(25):7809–14.
- 534 44. Krammer F. The human antibody response to influenza A virus infection and vaccination.
535 *Nat Rev Immunol.* 2019;19(6):383–97.
- 536 45. Reynolds HY. Immunoglobulin G and its function in the human respiratory tract. *Mayo*
537 *Clin Proc.* 1988 Feb;63(2):161–74.
- 538 46. Muramatsu M, Yoshida R, Yokoyama A, Miyamoto H, Kajihara M, Maruyama J, et al.
539 Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin:
540 increased potential of IgA for heterosubtypic immunity. *PloS One.* 2014;9(1):e85582.
- 541 47. Shen C, Zhang M, Chen Y, Zhang L, Wang G, Chen J, et al. An IgM antibody targeting
542 the receptor binding site of influenza B blocks viral infection with great breadth and potency.
543 *Theranostics.* 2019;9(1):210–31.
- 544 48. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, et al. Impaired
545 Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of
546 Adults with Respiratory Syncytial Virus. *Am J Respir Crit Care Med.* 2015 May 1;191(9):1040–
547 9.
- 548 49. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV--a

- 549 target for vaccine and therapeutic development. *Nat Rev Microbiol.* 2009 Mar;7(3):226–36.
- 550 50. Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. Viral
551 presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort
552 study. *Lancet Microbe.* 2020 Sep 25;
- 553 51. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al.
554 Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases.
555 *JAMA Cardiol.* 2020 Jul 27;
- 556 52. Remmelink M, De Mendonça R, D’Haene N, De Clercq S, Verocq C, Lebrun L, et al.
557 Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. *Crit*
558 *Care Lond Engl.* 2020 12;24(1):495.
- 559 53. Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Kojic EM, et al. A High Through-put
560 Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory
561 Syndrome Corona virus 2. *medRxiv.* 2020 Apr 17;2020.04.14.20059501.
- 562 54. Oguntuyo KY, Stevens CS, Hung C-T, Ikegame S, Acklin JA, Kowdle SS, et al.
563 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus
564 neutralization assay allows for cross-cohort comparisons of COVID-19 sera. *medRxiv.* 2020
565 Aug 15;2020.08.13.20157222.
- 566 55. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking
567 Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19
568 Virus. *Cell.* 2020 Aug 20;182(4):812-827.e19.
- 569 56. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG
570 antibody between male and female COVID-19 patients: a possible reason underlying different
571 outcome between gender. *medRxiv.* 2020 Mar 27;2020.03.26.20040709.

- 572 57. Fink AL, Engle K, Ursin RL, Tang W-Y, Klein SL. Biological sex affects vaccine
573 efficacy and protection against influenza in mice. *Proc Natl Acad Sci U S A*. 2018
574 04;115(49):12477–82.
- 575 58. Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, vom Steeg L, et al. Age-
576 associated changes in the impact of sex steroids on influenza vaccine responses in males and
577 females. *Npj Vaccines*. 2019 Jul 12;4(1):1–12.
- 578 59. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients
579 With COVID-19: Focus on Severity and Mortality. *Front Public Health* [Internet]. 2020 [cited
580 2020 Aug 6];8. Available from:
581 <https://www.frontiersin.org/articles/10.3389/fpubh.2020.00152/full>
- 582 60. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and
583 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020 Jun 18;1–
584 5.
- 585 61. Mazzini L, Martinuzzi D, Hyseni I, Lapini G, Benincasa L, Piu P, et al. Comparative
586 analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human
587 serum samples. *bioRxiv*. 2020 Aug 10;2020.08.10.243717.
- 588 62. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early
589 neutralizing antibody response to SARS-CoV-2. *medRxiv*. 2020 Jun 11;2020.06.10.20126532.
- 590 63. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and
591 saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol*
592 [Internet]. 2020 Oct 8 [cited 2020 Oct 9];5(52). Available from:
593 <https://immunology.sciencemag.org/content/5/52/eabe5511>
- 594 64. Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced

- 595 SARS-CoV-2 Neutralization by Secretory IgA in vitro. *bioRxiv*. 2020 Sep 9;2020.09.09.288555.
- 596 65. Horwitz, Bar-On Y, Lu C-L, Fera D, Lockhart AAK, Lorenzi JCC, et al. Non-
597 neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. *Cell*. 2017 Jul 26;
- 598 66. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al.
599 Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and
600 VAX003 vaccines. *Sci Transl Med*. 2014 Mar 19;6(228):228ra38.
- 601 67. Ilinykh PA, Huang K, Santos RI, Gilchuk P, Gunn BM, Karim MM, et al. Non-
602 neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector
603 Functions and by Enhancing Efficacy of Other Antibodies. *Cell Host Microbe*. 2020
604 10;27(6):976-991.e11.
- 605 68. Gunn BM, Yu W-H, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A Role for Fc
606 Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. *Cell*
607 *Host Microbe*. 2018 08;24(2):221-233.e5.
- 608 69. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. *Nat*
609 *Rev Immunol*. 2020;20(7):392-4.
- 610 70. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-
611 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*.
612 2020;583(7815):290-5.
- 613 71. Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, et al. SARS-CoV-2
614 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma
615 therapy. *MedRxiv Prepr Serv Health Sci*. 2020 Sep 18;
- 616 72. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early
617 Serological Signatures Track with SARS-CoV-2 Survival. *Immunity [Internet]*. 2020 Jul 30

618 [cited 2020 Aug 12]; Available from:

619 <http://www.sciencedirect.com/science/article/pii/S1074761320303277>

620 73. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot
621 Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature*. 2020 Jul 30;

622 74. Yu H-Q, Sun B-Q, Fang Z-F, Zhao J-C, Liu X-Y, Li Y-M, et al. Distinct features of
623 SARS-CoV-2-specific IgA response in COVID-19 patients. *Eur Respir J*. 2020;56(2).

624 75. Meyer-Bahlburg A. B-1 cells as a source of IgA. *Ann N Y Acad Sci*. 2015
625 Dec;1362:122–31.

626 76. Rodriguez-Zhurbenko N, Quach TD, Hopkins TJ, Rothstein TL, Hernandez AM. Human
627 B-1 Cells and B-1 Cell Antibodies Change With Advancing Age. *Front Immunol* [Internet].
628 2019 [cited 2020 Aug 6];10. Available from:

629 <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00483/full>

630 77. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et
631 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020 May
632 12;1–4.

633 78. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al.
634 SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen
635 Production, and Test Setup. *Curr Protoc Microbiol*. 2020;57(1):e100.

636

637

638 **Funding**

639 This study was supported by the Microbiology Laboratory Clinical Services at the Mount Sinai
640 Health System and the Mount Sinai Health System Translational Science Hub, National
641 Institutes of Health [grant U54TR001433]; the Personalized Virology Initiative supported by
642 institutional funds and philanthropic donations (to V.S.); the Department of Medicine of the
643 Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the
644 Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman
645 Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the National Institute of Allergy
646 and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [contract
647 HHSN272201400008C] (to F.K., V.S.); the Department of Veterans Affairs [Merit Review
648 Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to
649 C.E.H.); the National Institute of Allergy and Infectious Diseases [grant AI139290] to C.E.H.,
650 [grant AI136916] (to V.S.), [grants R01 AI123449, R21 AI1498033] to B.L.
651 K.Y.O. and C.S. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647;
652 K.Y.O. was additionally supported by F31 AI154739. S.I. and C-T. H. were supported by
653 postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of
654 Science and Technology (MOST, Taiwan), respectively.

655

656 **Acknowledgments**

657 We thank all the donors for their contribution to research.

658

659 **Competing interests**

660 The authors declare no competing interests.

661

662 **Author contributions**

663 J.K., S.W., G.E-A., S.Z-P., and C.E.H. wrote and edited the manuscript. S.W., J.K., C.E.H., and

664 S.Z-P. designed the experiments. J.K., S.W., V.I., X.L. performed the experiments and collected

665 the data. J.K., A.N., S.Z-P. and C.E.H. analyzed the data. K.Y.O., C.S., S.I., C-T.H., F.A., B.L.,

666 and F.K. provided protocols, antigens, cells and pseudovirus stocks. G.E-A., I.B., S.A., J.C.B.,

667 E.M.K., J.S., S.L., D.J., M.B-G., and V.S. provided samples. All authors read and approved the

668 final manuscript.

669

670 **Figure legends**

671 **Fig. 1. Titration of SARS-CoV-2 spike and RBD total Ig in plasma or serum samples from**
672 **COVID-19 convalescent individuals.** Titration of (a) spike-specific or (b) RBD-specific total Ig
673 from 29 COVID-19-convalescent individuals, two acute COVID-19 patients with longitudinal
674 samples, and 13 COVID-19-negative individuals. Specimens were diluted at 2-fold dilutions
675 from 1:50 to 1:6,400.

676 **Fig. 2. Levels of Ig isotypes against the SARS-CoV-2 spike and RBD vary in plasma or**
677 **serum samples from COVID-19 convalescent individuals.** Detection of total Ig, IgM, IgG1,
678 IgG2, IgG3, IgG4, IgA1 and IgA2 against (a) spike and (b) RBD in specimens from 29 COVID-
679 19-convalescent individuals, 13 COVID-19-negative contemporary samples, and pre-pandemic
680 controls. The samples were tested at a dilution of 1:200 and data are shown as mean MFI +
681 standard deviation (SD) of duplicate measurements from at least two independent experiments.
682 The pre-pandemic controls are shown as mean MFI + SD of 12 samples (Pre, black bar). The
683 horizontal red dotted line represents the cut-off value determined as the mean + 3 SD of 12 pre-
684 pandemic samples for each of the isotypes. (c) Percentages of responders above the cut-off for
685 each spike- or RBD-specific Ig isotype.

686 **Fig. 3. IgG1 is the dominant isotype response induced in COVID-19 convalescent**
687 **individuals.** Simple linear regression of (a) spike-specific or (b) RBD-specific total Ig levels
688 versus IgM, IgG1 or IgG2 levels or versus (c) spike-specific and RBD-specific IgG3, IgG4,
689 IgA1, and IgA2 levels from the 29 COVID-19-convalescent individuals from Fig. 1. The dash
690 lines represent 95% confidence intervals.

691 **Fig. 4. Neutralization activities are detected in all COVID-19 convalescent individuals.**
692 Neutralization of COV2pp with (a,b,c) WT or (d,e) D614G mutated spike proteins by samples

693 from (a,d) 28 COVID-19-convalescent individuals and (b,e) 11 COVID-19-negative individuals,
694 compared to (c) a recombinant soluble RBD (sRBD) control. Each plasma or sera specimen was
695 tested at 4-fold dilutions from 1:10 to 1:40,960, and sRBD was tested at 4-fold dilutions from
696 100 to 0.02 $\mu\text{g/mL}$. The data are shown as mean percentage of neutralization + SD of triplicate.
697 The extrapolated titration curves were generated using a nonlinear regression model in GraphPad
698 Prism (Inhibitor versus response – variable slope (four parameters), least squares regression).
699 The dotted horizontal lines highlight 50% neutralization. (f) Spearman correlation between the
700 IC_{90} titers against COV2pp WT versus D614G.

701 **Fig. 5. Summary of relative Ig isotype levels and neutralization titers.** Table showing sex
702 (purple, F: female, M: male), relative levels of spike-specific (green) and RBD-specific (blue) Ig
703 isotypes (+: bottom quartile, ++: second quartile, +++: third quartile, ++++: top quartile, -: non-
704 responder) and reciprocal IC_{50} and IC_{90} neutralization titers against WT pseudovirus (orange)
705 and D614G pseudovirus (red) of 29 plasma samples from COVID-19-convalescent individuals
706 (nd: not done).

707 **Fig. 6. IgM and IgG1 contribute most to SARS-CoV-2 neutralization.** Simple linear
708 regression of reciprocal IC_{90} neutralization titers of 27 COVID-19-convalescent individuals
709 versus (a) spike-specific or (b) RBD-specific total Ig, IgM, IgG1 and IgA1 Ab levels. The black
710 dash line shows 95% confidence interval. The dotted vertical red line represents the cut-off
711 (mean of 12 pre-pandemic samples + 3 SD) for each isotype from Fig. 1. (b) Simple linear
712 regression of reciprocal IC_{90} neutralization titers of 27 COVID-19-convalescent individuals
713 versus spike-specific or RBD-specific total IgG2-4 and IgA2 Ab levels.

714 **Fig. 7. Purified IgM, IgG, and IgA fractions display neutralizing activities against SARS-**
715 **CoV-2.** (a) Neutralization of COV2pp by five COVID-19-infected individual plasma samples

716 (RP#1-5) compared to a COVID-19-negative sample (RN#1). Plasma samples were tested at 4-
717 fold dilutions from 1:10 to 1:40,960 or 1:20 to 1:81,920. Data are shown as the mean percentage
718 of neutralization. The dotted horizontal lines highlight 50% neutralization. (b) Reciprocal IC_{50}
719 and IC_{90} neutralization titers of RP#1-5 plasma samples (c) Neutralization of COV2pp by
720 purified IgM, IgG, and IgA fractions from five COVID-19-infected individuals (RP#1-5)
721 compared to a control Ig fraction. The fractions were tested at 4-fold dilutions from 500 to 0.02
722 $\mu\text{g/mL}$. Data are shown as the mean percentage of neutralization. The dotted horizontal lines
723 highlight 50% neutralization. (d) IC_{50} of purified IgM, IgG, and IgA fractions from RP#1-5. The
724 statistical significance was determined by a two-tailed Mann-Whitney test (*: $p < 0.05$, **: $p <$
725 0.01).

726

727 **Supplementary Fig. 1.** Spearman correlations of (a) spike-specific or (b) RBD-specific total Ig
728 MFI values from two independent experiments to show the degree of assay reproducibility.

729 **Supplementary Fig. 2.** Spearman correlations of the area under the curves (AUCs) of (a) spike-
730 or (b) RBD-specific total Ig versus total Ig MFI values at a 1:200 dilution.

731 **Supplementary Fig. 3.** Isotyping validation was performed by coating Luminex beads with
732 IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and IgM myeloma proteins and detecting each specifically
733 with eight different secondary Abs against (a) total Ig, (b) IgM, (c) IgG1, (d) IgG2, (e) IgG3, (f)
734 IgG4, (g) IgA1 and (h) IgA2. The data are shown as mean MFI + SD of duplicate.

735 **Supplementary Fig. 4.** Spearman correlations between spike-specific versus RBD-specific total
736 Ig, IgM, IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2 MFI values.

737 **Supplementary Fig. 5.** Violin plots of (a) spike-specific or (b) RBD-specific total Ig, IgM,
738 IgG1, and IgA1 levels from nine COVID-19 convalescent female (F) and 15 male (M) subjects.


739 The statistical significance was determined by a two-tailed Mann-Whitney test (ns: non-
740 significant: $p > 0.05$).

741 **Supplementary Fig. 6. Induction of IgA1 and IgG1 along with IgM early after disease**

742 **onset.** Kinetics of induction of spike-specific (left panel) or RBD-specific (right panel) (a) total
743 Ig, (b) IgM, (c) IgG1, (d) IgG2, (e) IgG3, (f) IgG4, (g) IgA1, and (h) IgA2 from two COVID-19
744 patients. Longitudinal samples from each patient were tested at a dilution of 1:200 in parallel
745 with all negative samples and data are shown as mean MFI + SD of duplicate measurements
746 from at least two experiments. The dotted red line represents the cut-off value calculated as the
747 mean of 12 pre-pandemic samples + 3 SD from Fig. 1.

748 **Supplementary Fig. 7. Enrichment of spike-specific (a) IgM, (b) IgG, and (c) IgA in**

749 **purified fractions from RP#1-5 and RN#1.** Each fraction was measured for the presence of
750 IgM, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2 Abs using the isotyping method validated in
751 Supplementary Fig. 3.



- P#1a
- P#1b
- P#1c
- P#2a
- P#2b
- P#3
- P#4
- P#5
- P#6
- P#7
- P#8
- TF#1
- TF#2
- TF#3
- TF#4
- TF#5
- TF#6
- TF#7
- TF#8
- TF#9
- TF#10
- TF#11
- TF#12
- TF#13
- TF#14
- TF#15
- TF#16
- TF#17
- TF#18
- TF#19
- TF#20
- TF#21
- TF#22
- TF#23
- TF#24
- TF#25
- COVID-19-negative subjects

COVID-19-positive subjects












Fig. 1. Titration of SARS-CoV-2 spike and RBD total Ig in plasma or serum samples from COVID-19 convalescent individuals. Titration of (a) spike-specific or (b) RBD-specific total Ig from 29 COVID-19-convalescent individuals, two acute COVID-19 patients with longitudinal samples, and 13 COVID-19-negative individuals. Specimens were diluted at 2-fold dilutions from 1:50 to 1:6,400.

a**b****c**

	Spike	RBD
Total Ig	100%	100%
IgM	100%	93%
IgG1	97%	97%
IgG2	0%	0%
IgG3	7%	17%
IgG4	7%	3%
IgA1	97%	93%
IgA2	17%	48%

Fig. 2. Levels of Ig isotypes against the SARS-CoV-2 spike and RBD vary in plasma or serum samples from COVID-19 convalescent individuals. Detection of total Ig, IgM, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2 against (a) spike and (b) RBD in specimens from 29 COVID-19-convalescent individuals, 13 COVID-19-negative contemporary samples, and pre-pandemic controls. The samples were tested at a dilution of 1:200 and data are shown as mean MFI + standard deviation (SD) of duplicate measurements from at least two independent experiments. The pre-pandemic controls are shown as mean MFI + SD of 12 samples (Pre, black bar). The horizontal red dotted line represents the cut-off value determined as the mean + 3 SD of 12 pre-pandemic samples for each of the isotypes. (c) Percentages of responders above the cut-off for each spike- or RBD-specific Ig isotype.



c

	Linear regression spike MFI			Linear regression RBD MFI		
	r^2	p		r^2	p	
Total vs IgG3	0.35	0.0008	***	0.07	0.15	ns
Total vs IgG4	0.07	0.15	ns	0.24	0.007	***
Total vs IgA1	0.06	0.20	ns	0.23	0.009	***
Total vs IgA2	0.06	0.20	ns	0.13	0.05	ns

Fig. 3. IgG1 is the dominant isotype response induced in COVID-19 convalescent individuals. Simple linear regression of (a) spike-specific or (b) RBD-specific total Ig levels versus IgM, IgG1 or IgG2 levels or versus (c) spike-specific and RBD-specific IgG3, IgG4, IgA1, and IgA2 levels from the 29 COVID-19-convalescent individuals from Fig. 1. The dash lines represent 95% confidence intervals.

















Fig. 4. Neutralization activities are detected in all COVID-19 convalescent individuals.

Neutralization of COV2pp with (a,b,c) WT or (d,e) D614G mutated spike proteins by samples from (a,d) 28 COVID-19-convalescent individuals and (b,e) 11 COVID-19-negative individuals, compared to (c) a recombinant soluble RBD (sRBD) control. Each plasma or sera specimen was tested at 4-fold dilutions from 1:10 to 1:40,960, and sRBD was tested at 4-fold dilutions from 100 to 0.02 $\mu\text{g/mL}$. The data are shown as mean percentage of neutralization + SD of triplicate. The extrapolated titration curves were generated using a nonlinear regression model in GraphPad Prism (Inhibitor versus response – variable slope (four parameters), least squares regression). The dotted horizontal lines highlight 50% neutralization. (f) Spearman correlation between the IC_{90} titers against COV2pp WT versus D614G.


	Sex	Spike								RBD								Neutralization		Neutralization D614G mutant	
		Total Ig	IgM	IgG1	IgG2	IgG3	IgG4	IgA1	IgA2	Total Ig	IgM	IgG1	IgG2	IgG3	IgG4	IgA1	IgA2	IC ₅₀	IC ₉₀	IC ₅₀	IC ₉₀
P#5	unknown	++	+	+	-	-	-	++	-	+	-	+	-	-	-	+	+	36.6	2.3	nd	nd
P#6	unknown	+++	+	++	-	-	+	+	-	++	+	+	-	+	-	+	+	561.0	25.6	nd	nd
P#7	unknown	+	++	+	-	-	-	+	-	++	++	+	-	-	-	+	-	nd	nd	nd	nd
P#8	unknown	++	+	++	-	-	+	+	-	+	++	+	-	-	-	+	-	376.2	10.2	nd	nd
TF#1	F	+	+	+	-	-	-	+	-	++	+	++	-	-	-	+	-	418.8	21.5	254.8	28.6
TF#2	M	++	+	++	-	-	-	+	-	++	+	+	-	-	-	+	-	177.5	11.8	59.6	12.7
TF#3	M	++	+	+	-	-	-	+	-	++	+	+	-	-	-	+	+	164.7	19.8	206.2	87.5
TF#4	F	+	+	+	-	-	-	+	-	++	+	+	-	-	-	+	-	998.6	39.9	328.7	62.1
TF#5	M	++++	++	++++	-	-	-	++	-	++++	+++	+++	-	-	-	++	+	2344.7	515.9	4138.0	730.1
TF#6	F	++	+	+	-	-	-	+	-	++	+	++	-	+	-	+	-	976.6	51.9	551.8	99.7
TF#7	F	+++	+	++	-	+	-	++++	+	++++	+	++	-	-	-	++++	+	5788.5	90.7	452.5	81.2
TF#8	M	+	+	+	-	-	-	+	-	++	+	+	-	-	-	+	-	2840.0	142.1	700.1	129.1
TF#9	F	+++	++	++	-	-	-	+++	+	+++	++	++	-	+	-	++	+	4044.1	116.5	664.2	122.8
TF#10	M	++	+	+	-	-	-	+	-	+++	+	++	-	-	-	+	+	1060.0	72.7	572.1	75.0
TF#11	M	++	++++	+	-	-	-	+	-	++	++++	+	-	-	-	+	-	> 40960	7200.0	> 40960	2344.0
TF#12	F	+	+	+	-	-	-	+	-	++	++	+	-	-	-	+	-	285.5	30.0	325.7	54.12
TF#13	M	++	++	+	-	-	-	+++	+	++	+++	+	-	-	-	+	+	1697.6	144.9	1573.0	156.1
TF#14	M	+++	+	++	-	-	-	+	-	++	+	+	-	+	-	+	-	17078.5	201.4	675.2	151.1
TF#15	M	+++	+	++	-	-	-	-	-	+++	++	++	-	-	-	-	-	2006.2	29.6	548.5	67.9
TF#16	M	+++	+	++	-	-	-	+	+	+++	++	++	-	-	-	+	+	1330.7	106.2	1961.0	233.0
TF#17	M	++	+	+	-	-	-	+	-	+++	+	++	-	-	-	+	-	198.0	27.2	185.9	39.8
TF#18	F	++	+	++	-	-	-	++	-	+++	+	++	-	-	-	+	+	1122.1	56.9	453.8	64.4
TF#19	M	++	+	+	-	-	-	+	-	++	+	+	-	-	-	-	-	326.2	17.7	201.4	31.8
TF#20	F	++	+	++	-	-	-	++	-	+++	+++	++	-	+	-	+	+	1535.3	72.4	471.0	75.5
TF#21	M	++++	++	+++	-	+	-	++	-	++++	+++	++++	-	-	-	+	+	5375.7	389.7	3231.0	411.8
TF#22	M	++	+	++	-	-	-	+	-	+	-	++	-	-	-	+	+	623.2	4.8	46.65	11.5
TF#23	unknown	++	+	-	-	-	-	++	-	+++	+++	-	-	-	-	+	-	3881.9	107.8	563.7	170.9
TF#24	M	+	+	+	-	-	-	++	+	++	+	+	-	-	+	++	+	813.6	24.4	214.8	70.7
TF#25	F	+++	+	++	-	-	-	+	-	++++	+	++++	-	-	-	+	-	958.6	78.7	605.0	134.0

Fig. 5. Summary of relative Ig isotype levels and neutralization titers. Table showing sex (purple, F: female, M: male), relative levels of spike-specific (green) and RBD-specific (blue) Ig isotypes (+: bottom quartile, ++: second quartile, +++: third quartile, ++++: top quartile, -: non-responder) and reciprocal IC_{50} and IC_{90} neutralization titers against WT pseudovirus (orange) and D614G pseudovirus (red) of 29 plasma samples from COVID-19-convalescent individuals (nd: not done).

a**b****c**




	Linear regression IC ₉₀ versus Spike MFI			Linear regression IC ₉₀ versus RBD MFI		
	r ²	p		r ²	p	
IgG2	0.14	0.05	ns	0.33	0.002	**
IgG3	0.30	0.003	**	0.02	0.46	ns
IgG4	0.00	0.99	ns	0.06	0.21	ns
IgA2	0.02	0.50	ns	0.03	0.45	ns

Fig. 6. IgM and IgG1 contribute most to SARS-CoV-2 neutralization. Simple linear regression of reciprocal IC_{90} neutralization titers of 27 COVID-19-convalescent individuals versus (a) spike-specific or (b) RBD-specific total Ig, IgM, IgG1 and IgA1 Ab levels. The black dash line shows 95% confidence interval. The dotted vertical red line represents the cut-off (mean of 12 pre-pandemic samples + 3 SD) for each isotype from Fig. 1. (b) Simple linear regression of reciprocal IC_{90} neutralization titers of 27 COVID-19-convalescent individuals versus spike-specific or RBD-specific total IgG2-4 and IgA2 Ab levels.



b

	Neutralization	
	IC ₅₀	IC ₉₀
RP#1	240	35
RP#2	35	< 20
RP#3	290	60
RP#4	690	45
RP#5	690	100



- RP#1
- RP#2
- ▲ RP#3
- ◆ RP#4
- ★ RP#5
- △ Control Ig

Fig. 7. Purified IgM, IgG, and IgA fractions display neutralizing activities against


SARS-CoV-2. (a) Neutralization of COV2pp by five COVID-19-infected individual plasma samples (RP#1-5) compared to a COVID-19-negative sample (RN#1). Plasma samples were tested at 4-fold dilutions from 1:10 to 1:40,960 or 1:20 to 1:81,920. Data are shown as the mean percentage of neutralization. The dotted horizontal lines highlight 50% neutralization.

(b) Reciprocal IC₅₀ and IC₉₀ neutralization titers of RP#1-5 plasma samples (c)


Neutralization of COV2pp by purified IgM, IgG, and IgA fractions from five COVID-19-infected individuals (RP#1-5) compared to a control Ig fraction. The fractions were tested at 4-fold dilutions from 500 to 0.02 µg/mL. Data are shown as the mean percentage of

neutralization. The dotted horizontal lines highlight 50% neutralization. (d) IC₅₀ of purified IgM, IgG, and IgA fractions from RP#1-5. The statistical significance was determined by a

two-tailed Mann-Whitney test (*: p < 0.05, **: p < 0.01).

a**Spike**

Spearman $r = 0.9638$
 $p < 0.0001$


b**RBD**

Spearman $r = 0.9439$
 $p < 0.0001$


Supplementary Fig. 1. Spearman correlations of (a) spike-specific or (b) RBD-specific total Ig MFI values from two independent experiments to show the degree of assay reproducibility.

a









Spike

**b**









RBD











Supplementary Fig. 2. Spearman correlations of the area under the curves (AUCs) of (a) spike- or (b) RBD-specific total Ig versus total Ig MFI values at a 1:200 dilution.




Supplementary Fig. 3. Isotyping validation was performed by coating Luminex beads with IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and IgM myeloma proteins and detecting each specifically with eight different secondary Abs against (a) total Ig, (b) IgM, (c) IgG1, (d) IgG2, (e) IgG3, (f) IgG4, (g) IgA1 and (h) IgA2. The data are shown as mean MFI + SD of duplicate.




















Supplementary Fig. 4. Spearman correlations between spike-specific versus RBD-specific total Ig, IgM, IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2 MFI values.

a**b**

Supplementary Fig. 5. Violin plots of (a) spike-specific or (b) RBD-specific total Ig, IgM, IgG1, and IgA1 levels from nine COVID-19 convalescent female (F) and 15 male (M) subjects. The statistical significance was determined by a two-tailed Mann-Whitney test (ns: non-significant: $p > 0.05$).



Supplementary Fig. 6. Induction of IgA1 and IgG1 along with IgM early after disease onset. Kinetics of induction of spike-specific (left panel) or RBD-specific (right panel) (a) total Ig, (b) IgM, (c) IgG1, (d) IgG2, (e) IgG3, (f) IgG4, (g) IgA1, and (h) IgA2 from two COVID-19 patients. Longitudinal samples from each patient were tested at a dilution of 1:200 in parallel with all negative samples and data are shown as mean MFI + SD of duplicate measurements from at least two experiments. The dotted red line represents the cut-off value calculated as the mean of 12 pre-pandemic samples + 3 SD from Fig. 1.



Supplementary Fig. 7. Enrichment of spike-specific (a) IgM, (b) IgG, and (c) IgA in purified fractions from RP#1-5 and RN#1. Each fraction was measured for the presence of IgM, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2 Abs using the isotyping method validated in Supplementary Fig. 3.